



- (51) International Patent Classification:  
C07K 16/24 (2006.01)
- (21) International Application Number:  
PCT/US2016/066722
- (22) International Filing Date:  
14 December 2016 (14.12.2016)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
62/268,432 16 December 2015 (16.12.2015) US  
62/333,063 6 May 2016 (06.05.2016) US  
PCT/US2016/052006  
15 September 2016 (15.09.2016) US
- (71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).
- (72) Inventors: HSU, Hailing; 7264 Littler Court, Moorpark, California 93021 (US). KANNAN, Gunasekaran; 151 Crestview Circle, Daly City, California 94015 (US). WALKER, Kenneth W.; 175 Mesa Avenue, Newbury Park, California 91320 (US). HORTTER, Michelle; 455 Mariposa Drive, Camarillo, California 93012 (US). BELOUSKI, Edward J.; 761 Camino Las Conchas, Thousand Oaks, California 91360 (US).
- (74) Agents: GAUL, Timothy J. et al.; Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

**Published:**

- with international search report (Art. 21(3))

[Continued on next page]

(54) Title: ANTI-TL1A/ANTI-TNF-ALPHA BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF




Fig. 1

(57) Abstract: The present invention concerns antigen binding proteins that bind TL1A, including bispecific antigen binding proteins (e.g., antibodies) to TL1A and TNF- $\alpha$ . Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed to TL1A and the other to TNF- $\alpha$ . The bispecific antigen binding proteins may also be comprised in an IgG-scFv fusion, in which a conventional tetrameric antibody directed to one antigen is fused to a pair of single chain Fv units directed to the other. The bispecific antigen binding protein may also be comprised in an IgG-Fab fusion, in which a Fab molecule that binds to one antigen is fused to each heavy chain of a conventional tetrameric antibody directed to the other antigen. The invention further relates to uses of the anti-TL1A binding proteins and anti-TL1A/anti-TNF-alpha antigen binding proteins, and pharmaceutical formulations thereof.



— *with amended claims (Art. 19(1))*

**Date of publication of the amended claims:** 8 September 2017

— *with sequence listing part of description (Rule 5.2(a))*

**NEW CLAIMS**

What is claimed is:

1. An antigen binding protein comprising a TL1A binding entity and a second binding entity that is not a TL1A binding entity, wherein:
  - a. the TL1A binding entity has one or two light chain variable domains and one or two heavy chain variable domains;
  - b. the TL1A binding entity light chain variable domain comprises a LCDR1, LCDR2, and LCDR3;
  - c. the TL1A binding entity heavy chain variable domain comprises a HCDR1, HCDR2, and HCDR3; and
  - d. the HCDR1 has a sequence selected from Tables A, B, and C (SEQ ID NOS: 164, 170, 182, 188, 777, 783, 792, 798, 804, 809, 815, 819, 265, 836, 847, 857, 639, 654, 655, 632, 664, 955, 979, 994, 1010, 1017, 1022, 1027, 1028, 1029, 1037, 1045, 1087, 253, 256, 259, 262, 268, 271, 265, and 950);
  - e. the HCDR2 has a sequence selected from Tables A, B, and C (SEQ ID NOS: 166, 172, 178, 184, 190, 196, 202, 483, 485, 779, 785, 794, 800, 811, 817, 821, 827, 832, 838, 843, 849, 853, 859, 864, 640, 204, 678, 679, 644, 648, 649, 633, 656, 659, 660, 665, 666, 677, 114, 227, 230, 691, 715, 669, 711, 971, 972, 973, 974, 975, 980, 981, 982, 983, 984, 995, 996, 997, 998, 0999, 1011, 1023, 1030, 1038, 1039, 1040, 1041, 1042, 1046, 1047, 1048, 1058, 1059, 1060, 1061, 1062, 1066, 1067, 1068, 1069, 1070, 1074, 1088, 1089, 1090, 1095, 1096, 1097, 1102, 1103, 1104, 1108, 1109, 1110, 1111, 1112, 254, 260, 184, 269, 272, 266, 951, 953, 956, and 963); and
  - f. the HCDR3 sequence is selected from Tables A, B, and C (SEQ ID NOS: 168, 174, 180, 186, 192, 489, 641, 645, 650, 657, 676, 657, 667, 671, 255, 258, 261, 264, 267, 270, 273, 672, and 675).
2. The antigen binding protein of claim 1, wherein the HCDR3 comprises a sequence selected from Table A (SEQ ID NOS: 168, 174, 180, 186, 192, 489, 781, 787, 796, 802, 807, 813, 823, 829, 834, 840, 845, 851, 855, and 861).
3. The antigen binding protein of claim 2, wherein the HCDR3 has a sequence selected from antibodies and 9C8 and 3B3 (SEQ ID NO: 180 and 192).

4. The antigen binding protein of claim 2, wherein:
  - a. the HCDR1 has a sequence selected from Table A (SEQ ID NOS: 164, 170, 182, 188, 777, 783, 792, 798, 804, 809, 815, 819, 265, 836, 847, and 857) and
  - b. the HCDR2 has a sequence selected from Table A (SEQ ID NOS: 166, 172, 178, 184, 190, 196, 202, 483, 485, 779, 785, 794, 800, 811, 817, 821, 827, 832, 838, 843, 849, 853, 859, and 864).
5. The antigen binding protein of claim 3 wherein:
  - a. the HCDR1 has a sequence selected from antibodies 9C8 and 3B3 (SEQ ID NO: 170 and 188) and
  - b. the HCDR2 has a sequence selected from antibodies 9C8 and 3B3 (SEQ ID NO: 178 and 190).
6. The antigen binding protein of claim 1 wherein:
  - a. the LCDR1 has a sequence selected from Tables A, B, and C (SEQ ID NOS: 98, 104, 110, 116, 122, 128, 467, 469, 683, 689, 235, 697, 146, 709, 713, 719, 723, 229, 226, 741, 747, 753, 773, 635, 642, 646, 651, 658, 661, 668, 759, 743, 765, 977, 986, 987, 1001, 1016, 1021, 1025, 1031, 1032, 1033, 1044, 1053, 1064, 1072, 1078, 1079, 1080, 1106, 226, 229, 232, 235, 241, 238, , 1113, , 146, and 947);
  - b. the LCDR2 has a sequence selected from Tables A, B, and C (SEQ ID NOS: 100, 106, 112, 118, 124, 235, 699, 705, 721, 725, 731, 737, 749, 755, 761, 769, 636, 643, 647, 652, 662, 789, 988, 1001, 1002, 1004, 1026, 1054, 1073, 1081, 1082, 1083, 1084, 1085, 1092, 1098, 242, 935, 148, 948, and 943); and
  - c. the LCDR3 has a sequence selected from Tables A, B, and C (SEQ ID NOS: 102, 108, 263, 120, 126, 687, 693, 701, 707, 717, 727, 733, 739, 745, 751, 757, 763, 767, 771, 775, 637, 638, 631, 653, 663, 637, 233, 940, 978, 989, 990, 991, 992, 993, 1005, 1006, 1007, 1008, 1009, 1034, 1035, 1036, 1055, 1056, 1057, 1065, 1086, 1093, 1094, 1099, 1100, 1101, 1107, 228, 231, 234, 237, 243, 240, 674, 936, 938, 701, 707, , 949, , 942, and 944).
7. The antigen binding protein of claim 2 wherein the LCDR3 has a sequence selected from Table A (SEQ ID NOS: 102, 108, 263, 120, 126, 687, 693, 701, 707, 717, 727, 733, 739, 745, 751, 757, 763, 767, 771, and 775).

8. The antigen binding protein of claim 3 wherein the LCDR3 has a sequence selected from antibodies 9C8 and 3B3 (SEQ ID NOS: 263 and 126).
9. The antigen binding protein of claim 7, wherein:
  - a. the LCDR1 has a sequence selected from Table A (SEQ ID NOS: 98, 104, 110, 116, 122, 128, 467, 469, 683, 689, 235, 697, 146, 709, 713, 719, 723, 229, 226, 741, 747, 753, and 773) and
  - b. the LCDR2 has a sequence selected from Table A (SEQ ID NOS: 100, 106, 112, 118, 124, 685, 699, 705, 721, 725, 731, 737, 749, 755, 761, and 769).
10. The antigen binding protein of claim 8 wherein:
  - a. the LCDR1 has a sequence selected from antibodies 9C8 and 3B3 (SEQ ID NOS: 110 and 122) and
  - b. the LCDR2 has a sequence selected from antibodies 9C8 and 3B3 (SEQ ID NOS: 112 and 124).
11. The antigen binding protein of claim 1 wherein the heavy chain variable domain comprises a sequence at least about 90% identical to a heavy chain variable domain sequence selected from Table D (SEQ ID NOS: 8, 12, 16, 20, 24, 28, 32, 495, 497, 868, 872, 876, 880, 884, 888, 892, 896, 900, 904, 908, 912, 916, 920, 926, 930, and 934).
12. The antigen binding protein of claim 1 wherein the heavy chain variable domain comprises a heavy chain variable domain sequence selected from Table D (SEQ ID NOS: 8, 12, 16, 20, 24, 28, 32, 495, 497, 868, 872, 876, 880, 884, 888, 892, 896, 900, 904, 908, 912, 916, 920, 926, 930, and 934).
13. The antigen binding protein of claim 1 wherein the heavy chain variable domain comprises a heavy chain variable domain sequence selected from antibodies 9C8 and 3B3 (SEQ ID NOS: 16 and 24).
14. The antigen binding protein of claim 1, wherein the light chain variable domain comprises a sequence at least about 90% identical to a light chain variable domain sequence selected from Table D (SEQ ID NOS: 6, 10, 14, 18, 22, 26, 30, 491, 493, 866, 870, 874, 878, 882, 886, 890, 894, 898, 902, 906, 910, 914, 918, 922, 924, 928, and 932).
15. The antigen binding protein of claim 1, wherein the light chain variable domain comprises a light chain variable domain sequence selected from Table D (SEQ ID NOS:

- 6, 10, 14, 18, 22, 26, 30, 491, 493, 866, 870, 874, 878, 882, 886, 890, 894, 898, 902, 906, 910, 914, 918, 922, 924, 928, and 932).
16. The antigen binding protein of claim 11 wherein the light chain variable domain comprises a sequence at least about 90% identical to a light chain variable domain sequence selected from Table D (SEQ ID NOS: 6, 10, 14, 18, 22, 26, 30, 491, 493, 866, 870, 874, 878, 882, 886, 890, 894, 898, 902, 906, 910, 914, 918, 922, 924, 928, and 932).
  17. The antigen binding protein of claim 12 wherein the light chain variable domain comprises a light chain variable domain sequence selected from Table D (SEQ ID NOS: 6, 10, 14, 18, 22, 26, 30, 491, 493, 866, 870, 874, 878, 882, 886, 890, 894, 898, 902, 906, 910, 914, 918, 922, 924, 928, and 932).
  18. The antigen binding protein of claim 13 wherein the light chain variable domain sequence comprises a light chain variable domain sequence selected from antibodies 9C8 and 3B3 (SEQ ID NOS: 14 and 22).
  19. The antigen binding protein of claim 1 wherein the protein comprises a heavy chain having a heavy chain sequence selected from Table E (SEQ ID NOS: 52, 56, 60, 64, 68, 72, 76, 457, 461, 1118, 1122, 1126, 1130, 1134, 1138, 1142, 1146, 1150, 1154, 1158, 1162, 1166, 1170, 1174, 1178, 1182, 1186 and 1190).
  20. The antigen binding protein of claim 1 wherein the protein comprises a light chain having a light chain sequence selected from Table E (SEQ ID NOS: 66, 54, 58, 62, 66, 70, 74, 455, 459, 1116, 1120, 1124, 1128, 1132, 1136, 1140, 1144, 1148, 1152, 1156, 1160, 1164, 1168, 1172, 1176, 1180, 1184 and 1188).
  21. The antigen binding protein of claim 1 comprising the light and heavy chain sequences of an antibody selected from Table E, SEQ ID NOS:
    - a. 50 and 52,
    - b. 54 and 56,
    - c. 58 and 60,
    - d. 62 and 64,
    - e. 66 and 68,
    - f. 70 and 72,
    - g. 74 and 76,

- h. 455 and 457,
  - i. 459 and 461
  - j. 1116 and 1118,
  - k. 1120 and 1122,
  - l. 1124 and 1126,
  - m. 1128 and 1130,
  - n. 1132 and 1134,
  - o. 1136 and 1138,
  - p. 1140 and 1142,
  - q. 1144 and 1146,
  - r. 1148 and 1150,
  - s. 1152 and 1154,
  - t. 1156 and 1158,
  - u. 1160 and 1162,
  - v. 1164 and 1166,
  - w. 1168 and 1170,
  - x. 1172 and 1174,
  - y. 1176 and 1178,
  - z. 1180 and 1182,
  - aa. 1184 and 1186, and
  - bb. 1188 and 1190.
22. The antigen binding protein of claims 1 to 21, wherein the second binding entity is a TNF- $\alpha$  binding entity.
23. The antigen binding protein of claim 22, wherein:
- a. the TNF- $\alpha$  binding entity has one or two light chain variable domains and one or two heavy chain variable domains;
  - b. the TNF- $\alpha$  binding entity light chain variable domain comprises an LCDR1, LCDR2, and LCDR3; and
  - c. the TNF- $\alpha$  binding entity heavy chain variable domain comprises an HCDR1, HCDR2, and HCDR3.

24. The antigen binding protein of claim 23, wherein the TNF- $\alpha$  binding entity HCDR3 comprises a sequence selected from Table G (SEQ ID NOS: 162, 222, 210, and 216).
25. The antigen binding protein of claim 23, wherein the TNF- $\alpha$  binding entity HCDR3 comprises a sequence selected from certolizumab (SEQ ID NO: 222).
26. The antigen binding protein of claim 24, wherein:
  - a. the TNF- $\alpha$  binding entity HCDR1 comprises a sequence selected from Table G (SEQ ID NOS: 158, 218, 206, and 212); and
  - b. the TNF- $\alpha$  binding entity HCDR2 comprises a sequence selected from Table G (SEQ ID NOS: 160, 220, 208, and 214).
27. The antigen binding protein of claim 26 wherein the TNF binding entity light chain sequence comprises:
  - a. an LCDR1 sequence selected from Table G (SEQ ID NOS: 92, 152, 140, and 146),
  - b. an LCDR2 sequence selected from Table G (SEQ ID NOS: 94, 154, 112, and 148),  
and
  - c. an LCDR3 sequence selected from Table G (SEQ ID NOS: 96, 156, 144, and 150).
28. The antigen binding protein of claim 23, wherein the TNF binding entity heavy chain variable domain comprises a sequence at least about 90% identical to a heavy chain variable domain sequence selected from Table H (SEQ ID NOS: 4, 44, 318, 40, and 36).
29. The antigen binding protein of claim 23, wherein the TNF binding entity heavy chain variable domain sequence is a heavy chain variable domain sequence selected from Table H (SEQ ID NOS: 4, 44, 318, 40, and 36).
30. The antigen binding protein of claim 23, wherein the TNF- $\alpha$  binding entity light chain variable domain comprises a sequence at least about 90% identical to a light chain variable domain sequence selected from Table H (SEQ ID NOS: 2, 42, 38, and 34).
31. The antigen binding protein of claim 23, wherein the TNF binding entity comprises light chain variable domain sequence is a light chain variable domain sequence selected from Table H (SEQ ID NOS: 2, 42, 38, and 34).
32. The antigen binding protein of claim 28, wherein the TNF- $\alpha$  binding entity light chain variable domain comprises a sequence at least about 90% identical to a light chain variable domain sequence selected from Table H (SEQ ID NOS: 2, 42, 38, and 34).

33. The antigen binding protein of claim 29, wherein the TNF binding entity light chain variable domain sequence is a light chain variable domain sequence selected from Table H (SEQ ID NOS: 2, 42, 38, and 34).
34. The antigen binding protein of claim 23, wherein the antigen binding protein comprises variable region sequences selected from an antigen binding protein in Table I, SEQ ID NOS:
- a. 42, 286, 288, and 290;
  - b. 42, 44, 292, and 294;
  - c. 42, 44, 296, and 298;
  - d. 42, 44, 300 and 302;
  - e. 42, 44, 304, and 306;
  - f. 42, 44, 308, and 310;
  - g. 312, 314, 288, and 290;
  - h. 312, 314, 292, and 294;
  - i. 312, 314, 300 and 302;
  - j. 312, 314, 304, and 306;
  - k. 312, 314, 308, and 310;
  - l. 42, 318, 288, and 290;
  - m. 42, 318, 292, and 294;
  - n. 42, 318, 296, and 298;
  - o. 42, 318, 304, and 306;
  - p. 42, 318, 308, and 310;
  - q. 320, 322, 288, and 290;
  - r. 320, 322, 292, and 294;
  - s. 320, 322, 31, and 298;
  - t. 320, 322, 300, and 302;
  - u. 320, 322, 304, and 306; or
  - v. 320, 322, 308, and 310.
35. The antigen binding protein of claim 23, wherein:
- a. the heavy and light chains are IgG1, IgG2, or IgG4;

- b. the antigen binding protein comprises one TL1A binding entity heavy chain variable domain, one TL1A binding entity light chain variable domain, one TNF- $\alpha$  binding entity heavy chain variable domain, and one TNF- $\alpha$  binding entity light chain variable domain;
  - c. the TL1A binding entity light chain variable domain is comprised in a light chain separate from the TL1A binding entity heavy chain variable domain, the TNF- $\alpha$  binding entity heavy chain variable domain, and the TNF- $\alpha$  binding entity light chain variable domain;
  - d. the TL1A binding entity heavy chain variable domain is comprised in a heavy chain separate from the TL1A binding entity light chain variable domain, the TNF- $\alpha$  binding entity heavy chain variable domain, and the TNF- $\alpha$  binding entity light chain variable domain;
  - e. the TNF- $\alpha$  binding entity heavy chain variable domain is comprised in a heavy chain separate from the TNF- $\alpha$  binding entity light chain domain, the TL1A binding entity heavy chain variable domain, and the TL1A binding entity light chain variable domain;
  - f. the heavy chain comprising the TL1A binding entity heavy chain variable domain is covalently bound to the light chain comprising the TL1A binding entity light chain variable domain;
  - g. the heavy chain comprising the TNF- $\alpha$  binding entity heavy chain variable domain is covalently bound to the light chain comprising the TNF- $\alpha$  binding entity light chain variable domain; and
  - h. the heavy chain comprising the TL1A binding entity heavy chain variable domain is covalently bound to the heavy chain comprising the TNF- $\alpha$  binding entity heavy chain variable domain.
36. The antigen binding protein of claim 35, wherein:
- a. the TL1A binding entity light chain sequence comprises:
    - i. an LCDR1 sequence selected from Tables A, B, and C (SEQ ID NOS: 98, 104, 110, 116, 122, 128, 467, 469, 635, 642, 646, 651, 658, 661, 668, 226, 229, 232, 235, 241, 238 and) and

- ii. an LCDR2 sequence selected from Tables A, B, and C (SEQ ID NOS: 100, 106, 112, 118, 124, 636, 643, 647, 652, 662, 227, 230, 233, 242, and 473);
  - iii. an LCDR3 sequence selected from Tables A, B, and C (SEQ ID NOS: 102, 108, 263, 120, 126, 637, 638, 631, 653, 663, 228, 231, 234, 237, 243, 240, and 674),
  - b. the TL1A binding entity heavy chain sequence comprises:
    - i. an HCDR1 sequence selected from Tables A, B, and C (SEQ ID NOS: 164, 170, 182, 188, 639, 654, 655, 632, 664, 253, 256, 259, 262, 268, 271, and 265),
    - ii. an HCDR2 sequence selected from Tables A, B, and C (SEQ ID NOS: 166, 172, 178, 184, 190, 196, 202, 483, 485, 640, 204, 644, 648, 633, 656, 659, 660, 665, 666, 114, 669, 254, 172, 260, 184, 269, 272, 266, and 254), and
    - iii. an HCDR3 sequence selected from Tables A, B, and C (SEQ ID NOS: 168, 174, 180, 186, 192, 489, 641, 645, 650, 657, 676, 657, 667, 671, 255, 258, 261, 264, 267, 270, 273, 672, and 675);
  - c. the TNF- $\alpha$  binding entity light chain sequence comprises:
    - i. an LCDR1 sequence selected from Table G (SEQ ID NOS: 92, 152, 140, and 146),
    - ii. an LCDR2 sequence selected from Table G (SEQ ID NOS: 94, 154, 112, and 148), and
    - iii. an LCDR3 sequence selected from Table G (SEQ ID NOS: 96, 156, 144, and 150); and
  - d. the TNF- $\alpha$  binding entity heavy chain sequence comprises:
    - i. an HCDR1 sequence selected from Table G (SEQ ID NOS: 158, 218, 206, and 212),
    - ii. an HCDR2 sequence selected from Table G (SEQ ID NOS: 160, 220, 208, and 214), and
    - iii. an HCDR3 sequence selected from Table G (SEQ ID NOS: 162, 222, 210, and 216).
37. The antigen binding protein of claim 36, wherein:
- a. the TL1A binding entity light chain sequence comprises:
    - i. an LCDR1 sequence selected from Table A (SEQ ID NOS: 98, 104, 110, 116, 122, 128, 467, and 469),

- ii. an LCDR2 sequence selected from Table A (SEQ ID NOS: 100, 106, 112, 118, and 124);
  - iii. an LCDR3 sequence selected from Table A (SEQ ID NOS: 102, 108, 263, 120, and 126),
  - b. the TL1A binding entity heavy chain sequence comprises:
    - i. an HCDR1 sequence selected from Table A (SEQ ID NOS: 164, 170, 182, and 188),
    - ii. an HCDR2 sequence selected from Table A (SEQ ID NOS: 166, 172, 178, 184, 190, 196, 202, 483, and 485), and
    - iii. an HCDR3 sequence selected from Table A (SEQ ID NOS: 168, 174, 180, 186, 192, and 489).
38. The antigen binding protein of claim 35, wherein the antigen binding protein comprises variable region sequences selected from an antigen binding protein in Table I, SEQ ID NOS:
- a. 42, 286, 288, and 290;
  - b. 42, 44, 292, and 294;
  - c. 42, 44, 296, and 298;
  - d. 42, 44, 300 and 302;
  - e. 42, 44, 304, and 306;
  - f. 42, 44, 308, and 310;
  - g. 312, 314, 288, and 290;
  - h. 312, 314, 292, and 294;
  - i. 312, 314, 300 and 302;
  - j. 312, 314, 304, and 306;
  - k. 312, 314, 308, and 310;
  - l. 42, 318, 288, and 290;
  - m. 42, 318, 292, and 294;
  - n. 42, 318, 296, and 298;
  - o. 42, 318, 304, and 306;
  - p. 42, 318, 308, and 310;
  - q. 320, 322, 288, and 290;

- r. 320; 322, 292, and 294;
  - s. 320, 322, 31, and 298;
  - t. 320, 322, 300, and 302;
  - u. 320, 322, 304, and 306; or
  - v. 320, 322, 308, and 310.
39. The antigen binding protein of claim 38, wherein the antigen binding protein comprises sequences selected from an antigen binding protein in Table J, SEQ ID NOS:
- i. 132, 136, 134, and 130;
  - j. 132, 136, 239, and 138;
  - k. 132, 136, 253, and 323;
  - l. 132, 136, 327, and 325;
  - m. 132, 136, 331, and 329;
  - n. 132, 136, 335, and 329;
  - o. 337, 339, 134, and 130;
  - p. 337, 339, 323, and 253;
  - q. 337, 339, 327, and 325;
  - r. 337, 339, 331, and 329;
  - s. 337, 339, 335, and 329;
  - t. 132, 316, 239, and 138;
  - u. 132, 316, 323, and 253;
  - v. 132, 316, 335, and 329;
  - w. 132, 316, 331, and 329;
  - x. 333, 316, 134, and 130;
  - y. 333, 316, 239, and 138;
  - z. 333, 463, 323, and 253;
  - aa. 333, 463, 331, and 329;
  - bb. 333, 463, 335, and 329;
  - cc. 341, 343, 134, and 130;
  - dd. 341, 343, 239, and 138;
  - ee. 341, 343, 323, and 253;
  - ff. 341, 343, 327, and 325;

gg.	341, 343, 331, and 329;
hh.	341, 343, 335, and 329;
ii.	510, 514, 512, and 555;
jj.	510, 514, 541, and 558;
kk.	510, 514, 539, and 562;
ll.	510, 514, 543, and 565;
mm.	510, 514, 543, and 568;
nn.	510, 514, 544, and 568;
oo.	542, 571, 512, and 555;
pp.	542, 571, 541, and 558;
qq.	542, 571, 539, and 562;
rr.	542, 571, 543, and 565;
ss.	542, 571, 543, and 568;
tt.	542, 571, 544, and 568;
uu.	510, 573, 512, and 555;
vv.	510, 573, 541, and 558;
ww.	510, 573, 539, and 562;
xx.	510, 573, 543, and 568;
yy.	510, 573, 544, and 568;
zz.	540, 573, 512, and 555;
aaa.	540, 573, 541, and 558;
bbb.	540, 573, 539, and 562;
ccc.	540, 573, 543, and 568;
ddd.	540, 573, 544, and 568;
eee.	540, 487, 512, and 555;
fff.	540, 487, 541, and 558;
ggg.	540, 487, 539, and 562;
hhh.	540, 487, 543, and 568;
iii.	540, 487, 544, and 568;
jjj.	518, 522, 512, and 555;
kkk.	518, 522, 541, and 558;

lll.	518, 522, 539, and 562;
mmm.	518, 522, 543, and 565;
nnn.	518, 522, 543, and 568;
ooo.	518, 522, 544, and 568;
ppp.	545, 578, 546, and 579;
qqq.	545, 578, 548, and 562;
rrr.	545, 578, 549, and 585;
uu.	545, 578, 551, and 591;
uuu.	545, 578, 552, and 591;
vvv.	547, 595, 546, and 579;
www.	547, 595, 548, and 582;
xxx.	547, 595, 549, and 585;
yyy.	547, 595, 550, and 588;
zzz.	547, 595, 551, and 591;
aaaa.	547, 595, 552, and 591;
bbbb.	132, 599, 134, and 598;
cccc.	132, 599, 239, and 601;
dddd.	132, 599, 323, and 603;
eeee.	132, 599, 327, and 603;
ffff.	132, 599, 331, and 607;
gggg.	132, 599, 335, and 607;
hhhh.	337, 609, 134, and 598;
iiii.	337, 609, 239, and 601;
jjjj.	337, 609, 323, and 603;
kkkk.	337, 609, 327, and 605;
llll.	337, 609, 335, and 607;
mmmm.	132, 611, 134, and 598;
nnnn.	132, 611, 239, and 601;
oooo.	132, 611, 323, and 603;
pppp.	132, 611, 331, and 607;

qqqq. 132, 611, 335, and 607;  
rrrr. 333, 611, 134, and 598;  
ssss. 333, 611, 239, and 601;  
tttt. 333, 611, 323, and 603;  
uuuu. 333, 611, 331, and 607;  
vvvv. 333, 611, 335, and 607;  
wwww. 333, 613, 134, and 598;  
xxxx. 333, 613, 239, and 601;  
yyyy. 333, 613, 323, and 603;  
zzzz. 333, 613, 335, and 607;  
aaaaa. 341, 615, 134, and 598;  
bbbbb. 341, 615, 239, and 601;  
ccccc. 341, 615, 323, and 603;  
ddddd. 341, 615, 327, and 605;  
eeeee. 341, 615, 331, and 607;  
fffff. 341, 615, 335, and 607;  
ggggg. 333, 613, 331, and 607;  
hhhhh. 132, 463, 239, and 138;  
iiii. 132, 463, 331, and 329;  
jjjj. 132, 463, 335, and 320;  
kkkkk. 510, 487, 512, and 555;  
llll. 510, 487, 541, and 558;  
mmmmm. 510, 487, 543, and 568;  
nnnnn. 510, 487, 544, and 568;  
ooooo. 132, 613, 134, and 598;  
ppppp. 132, 613, 323, and 603;  
qqqqq. 132, 613, 331, and 607;  
rrrrr. 132, 613, 335, and 607;  
sssss. 132, 463, 134, and 130;  
ttttt. 540, 616, 512, and 508;  
uuuuu. 540, 620, 512, and 508;

- vvvvv. 540, 616, 541, and 558;  
wwwww. 540, 616, 539, and 562;  
xxxxx. 540, 620, 539, and 562;  
yyyyy. 538, 623, 512, and 502;  
zzzzz. 537, 626, 512, and 508;  
aaaaa. 546, 514, 194, and 535;  
bbbbb. 536, 616, 194, and 535;  
ccccc. 536, 620, 194, and 535;  
ddddd. 546, 487, 194, and 535;  
eeeee. 471, 136, 473, and 198;  
fffff. 176, 136, 520, and 198;  
ggggg. 475, 477, 520, and 198;  
hhhhh. 471, 463, 473, and 198;  
iiiiii. 176, 463, 473, and 198;  
jjjjj. 471, 465, 473, and 198;  
kkkkk. 176, 463, 570, and 198;  
lllll. 471, 465, 473, and 198;  
mmmmm. 176, 465, 520, and 198;  
nnnnn. 510, 514, 512, and 508;  
ooooo. 518, 522, 512, and 508;  
ppppp. 540, 616, 512, and 508;  
qqqqq. 540, 620, 512, and 508; and  
rrrrr. 537, 626, 512, and 508.
40. The antigen binding protein of claim 39, wherein the antigen binding protein comprises the sequences of iPS No. 376543 (SEQ ID NOS: 510, 516, 512, and 508).
41. The antigen binding protein of claim 35, wherein:
- one heavy chain comprises substitutions K392D and K409D and the other heavy chain comprises substitutions E356K and D399K using EU numbering; or
  - one heavy chain comprises substitutions K392D, K409D and K370D and the other heavy chain comprises substitutions E356K, D399K and E357K using EU numbering.

42. The antigen binding protein of claim 35, wherein:
- a. one heavy chain comprises substitution S183K, the other heavy chain comprises substitution S183E, one light chain comprises substitution S176E, and the other light chain comprises substitution S176K using EU numbering; or
  - b. one heavy chain comprises substitutions Q39K and S183K, the other heavy chain comprises substitutions Q39E and S183E, one light chain comprises substitutions Q38E and S176E, and the other light chain comprises substitutions Q38K and S176K using EU numbering; or
  - c. one heavy chain comprises substitutions G44K and S183K, the other heavy chain comprises substitutions G44E and S183E, one light chain comprises substitutions G100E and S176E, and the other light chain comprises substitutions G100K and S176K using EU numbering; or
  - d. one heavy chain comprises substitution S183K, the other heavy chain comprises substitution S183E, one light chain comprises substitution S176E, and the other light chain comprises substitution S176K using EU numbering.
43. The antigen binding protein of claim 41, wherein:
- a. one heavy chain comprises substitution S183K, the other heavy chain comprises substitution S183E, one light chain comprises substitution S176E, and the other light chain comprises substitution S176K using EU numbering; or
  - b. one heavy chain comprises substitutions Q39K and S183K, the other heavy chain comprises substitutions Q39E and S183E, one light chain comprises substitutions Q38E and S176E, and the other light chain comprises substitutions Q38K and S176K using EU numbering; or
  - c. one heavy chain comprises substitutions G44K and S183K, the other heavy chain comprises substitutions G44E and S183E, one light chain comprises substitutions G100E and S176E, and the other light chain comprises substitutions G100K and S176K using EU numbering; or
  - d. one heavy chain comprises substitution S183K, the other heavy chain comprises substitution S183E, one light chain comprises substitution S176E, and the other light chain comprises substitution S176K using EU numbering.

44. The antigen binding protein of claim 35, wherein the bispecific antigen binding protein comprises two IgG1 heavy chains comprising substitutions R292C, V302C and N297G using EU numbering.
45. The antigen binding protein of claim 41, wherein the bispecific antigen binding protein comprises two IgG1 heavy chains comprising substitutions R292C, V302C and N297G using EU numbering.
46. The antigen binding protein of claim 40, wherein the bispecific antigen binding protein comprises two IgG1 heavy chains comprising substitutions R292C, V302C and N297G using EU numbering.
47. The antigen binding protein of claim 43, wherein the bispecific antigen binding protein comprises two IgG1 heavy chains comprising substitutions R292C, V302C and N297G using EU numbering.
48. The antigen binding protein of claim 23, wherein:
  - a. the antigen binding protein comprises two light chains and two heavy chains;
  - b. the heavy and light chains comprise IgG1, IgG2, or IgG4 constant domains;
  - c. the antigen binding protein comprises two TL1A binding entity heavy chain variable domains, two TL1A binding entity light chain variable domains, two TNF- $\alpha$  binding entity heavy chain variable domains, and two TNF- $\alpha$  binding entity light chain variable domains;
  - d. each light chain comprises a TL1A binding entity light chain variable domain sequence; and
  - e. each heavy chain comprises a TL1A binding entity heavy chain variable domain sequence, a TNF- $\alpha$  binding entity heavy chain variable domain sequence and a TNF- $\alpha$  binding entity light chain variable domain sequence.
49. The antigen binding protein of claim 48, wherein:
  - a. the TL1A binding entity light chain sequence comprises:
    - i. an LCDR1 sequence selected from Tables A, B, and C (SEQ ID NOS: 98, 104, 110, 116, 122, 128, 467, 469, 635, 642, 646, 651, 658, 661, 668, 226, 229, 232, 235, 241, 238 and) and
    - ii. an LCDR2 sequence selected from Tables A, B, and C (SEQ ID NOS: 100, 106, 112, 118, 124, 636, 643, 647, 652, 662, 227, 230, 233, 242, and 473);

- iii. an LCDR3 sequence selected from Tables A, B, and C (SEQ ID NOS: 102, 108, 263, 120, 126, 637, 638, 631, 653, 663, 228, 231, 234, 237, 243, 240, and 674),
- b. the TL1A binding entity heavy chain sequence comprises:
  - i. an HCDR1 sequence selected from Tables A, B, and C (SEQ ID NOS: 164, 170, 182, 188, 639, 654, 655, 632, 664, 253, 256, 259, 262, 268, 271, and 265),
  - ii. an HCDR2 sequence selected from Tables A, B, and C (SEQ ID NOS: 166, 172, 178, 184, 190, 196, 202, 483, 485, 640, 204, 644, 648, 633, 656, 659, 660, 665, 666, 114, 669, 254, 172, 260, 184, 269, 272, 266, and 254), and
  - iii. an HCDR3 sequence selected from Tables A, B, and C (SEQ ID NOS: 168, 174, 180, 186, 192, 489, 641, 645, 650, 657, 676, 657, 667, 671, 255, 258, 261, 264, 267, 270, 273, 672, and 675);
- c. the TNF- $\alpha$  binding entity light chain sequence comprises:
  - i. an LCDR1 sequence selected from Table G (SEQ ID NOS: 92, 152, 140, and 146),
  - ii. an LCDR2 sequence selected from Table G (SEQ ID NOS: 94, 154, 112, and 148), and
  - iii. an LCDR3 sequence selected from Table G (SEQ ID NOS: 96, 156, 144, and 150); and
- d. the TNF- $\alpha$  binding entity heavy chain sequence comprises:
  - i. an HCDR1 sequence selected from Table G (SEQ ID NOS: 158, 218, 206, and 212),
  - ii. an HCDR2 sequence selected from Table G (SEQ ID NOS: 160, 220, 208, and 214), and
  - iii. an HCDR3 sequence selected from Table G (SEQ ID NOS: 162, 222, 210, and 216).
- l. The antigen binding protein of claim 49, wherein:
  - a. the TL1A binding entity light chain sequence comprises:
    - i. an LCDR1 sequence selected from Table A (SEQ ID NOS: 98, 104, 110, 116, 122, 128, 467, and 469),
    - ii. an LCDR2 sequence selected from Table A (SEQ ID NOS: 100, 106, 112, 118, and 124);

- iii. an LCDR3 sequence selected from Table A (SEQ ID NOS: 102, 108, 263, 120, and 126),
  - b. the TL1A binding entity heavy chain sequence comprises:
    - i. an HCDR1 sequence selected from Table A (SEQ ID NOS: 164, 170, 182, and 188),
    - ii. an HCDR2 sequence selected from Table A (SEQ ID NOS: 166, 172, 178, 184, 190, 196, 202, 483, and 485), and
    - iii. an HCDR3 sequence selected from Table A (SEQ ID NOS: 168, 174, 180, 186, 192, and 489).
- 51. The antigen binding protein of claim 48, wherein:
  - a. the TL1A binding entity heavy chain variable domain comprises a heavy chain variable domain sequence selected from Table D (SEQ ID NOS: 8, 12, 16, 20, 24, 28, and 32);
  - b. the TL1A binding entity light chain variable domain comprises a light chain variable domain sequence selected from Table D (SEQ ID NOS: 6, 10, 14, 18, 22, 26, and 30);
  - c. the TNF- $\alpha$  binding entity light chain variable domain sequence is selected from Table H (SEQ ID NOS: 2, 42, 38, and 34) and
  - d. the TNF- $\alpha$  binding entity heavy chain variable domain sequence is selected from Table H (SEQ ID NOS: 4, 44, 318, 40, and 36).
- 52. The antigen binding protein of claim 48, wherein the anti-TNF- $\alpha$  binding entity heavy chain variable domain comprises a cysteine residue at position 44 and the anti-TNF- $\alpha$  light chain binding domain comprises a cysteine residue at position 100, numbering as in Kabat.
- 53. The antigen binding protein of claim 48 wherein the protein comprises the heavy and light chain sequences of an antigen binding protein selected from Table L, SEQ ID NOS:
  - a. 355 and 447,
  - b. 357 and 447,
  - c. 359 and 447,
  - d. 361 and 447,
  - e. 363 and 447,
  - f. 365 and 58,

- g. 367 and 70,
  - h. 369 and 70,
  - i. 371 and 70,
  - j. 373 and 70,
  - k. 375 and 70,
  - l. 377 and 70,
  - m. 391 and 467,
  - n. 391 and 66,
  - o. 395 and 66,
  - p. 397 and 66,
  - q. 399 and 66,
  - r. 401 and 66,
  - s. 403 and 66,
  - t. 405 and 66
  - u. 407 and 447,
  - v. 409 and 447,
  - w. 411 and 66,
  - x. 413 and 66,
  - y. 415 and 66,
  - z. 417 and 66,
  - aa. 419 and 70,
  - bb. 421 and 70,
  - cc. 423 and 70, and
  - dd. 425 and 70.
54. The antigen binding protein of claim 48 wherein:
- a. the light chain sequence comprises SEQ ID NO: 453 and the heavy chain sequence comprises SEQ ID NO: 441;
  - b. the light chain sequence comprises SEQ ID NO: 451 and the heavy chain sequence comprises SEQ ID NO: 433; or
  - c. the light chain sequence comprises SEQ ID NO: 453 and the heavy chain sequence comprises SEQ ID NO: 445.

55. The antigen binding protein of claim 23, wherein:
- a. the antigen binding protein comprises two light chains and two heavy chains;
  - b. the heavy and light chains comprise IgG1, IgG2, or IgG4 constant domains;
  - c. the antigen binding protein comprises two TL1A binding entity heavy chain variable domains, two TL1A binding entity light chain variable domains, two TNF- $\alpha$  binding entity heavy chain variable domains, and two TNF- $\alpha$  binding entity light chain variable domains;
  - d. each light chain comprises a TNF- $\alpha$  binding entity light chain sequence; and
  - e. each heavy chain comprises a TNF- $\alpha$  binding entity heavy chain sequence, a TL1A binding entity heavy chain binding domain sequence and a TL1A binding entity light chain binding domain sequence.
56. The antigen binding protein of claim 55, wherein:
- a. the TL1A binding entity light chain sequence comprises:
    - i. an LCDR1 sequence selected from Tables A, B, and C (SEQ ID NOS: 98, 104, 110, 116, 122, 128, 467, 469, 635, 642, 646, 651, 658, 661, 668, 226, 229, 232, 235, 241, 238 and) and
    - ii. an LCDR2 sequence selected from Tables A, B, and C (SEQ ID NOS: 100, 106, 112, 118, 124, 636, 643, 647, 652, 662, 227, 230, 233, 242, and 473);
    - iii. an LCDR3 sequence selected from Tables A, B, and C (SEQ ID NOS: 102, 108, 263, 120, 126, 637, 638, 631, 653, 663, 228, 231, 234, 237, 243, 240, and 674),
  - b. the TL1A binding entity heavy chain sequence comprises:
    - i. an HCDR1 sequence selected from Tables A, B, and C (SEQ ID NOS: 164, 170, 182, 188, 639, 654, 655, 632, 664, 253, 256, 259, 262, 268, 271, and 265),
    - ii. an HCDR2 sequence selected from Tables A, B, and C (SEQ ID NOS: 166, 172, 178, 184, 190, 196, 202, 483, 485, 640, 204, 644, 648, 633, 656, 659, 660, 665, 666, 114, 669, 254, 172, 260, 184, 269, 272, 266, and 254), and
    - iii. an HCDR3 sequence selected from Tables A, B, and C (SEQ ID NOS: 168, 174, 180, 186, 192, 489, 641, 645, 650, 657, 676, 657, 667, 671, 255, 258, 261, 264, 267, 270, 273, 672, and 675);
  - c. the TNF- $\alpha$  binding entity light chain sequence comprises:

- i. an LCDR1 sequence selected from Table G (SEQ ID NOS:92, 152, 140, and 146),
    - ii. an LCDR2 sequence selected from Table G (SEQ ID NOS: 94, 154, 112, and 148), and
    - iii. an LCDR3 sequence selected from Table G (SEQ ID NOS: 96, 156, 144, and 150); and
  - d. the TNF- $\alpha$  binding entity heavy chain sequence comprises:
    - i. an HCDR1 sequence selected from Table G (SEQ ID NOS:158, 218, 206, and 212),
    - ii. an HCDR2 sequence selected from Table G (SEQ ID NOS:160, 220, 208, and 214), and
    - iii. an HCDR3 sequence selected from Table G (SEQ ID NOS: 162, 222, 210, and 216).
- 57. The antigen binding protein of claim 56, wherein:
  - a. the TL1A binding entity light chain sequence comprises:
    - i. an LCDR1 sequence selected from Table A (SEQ ID NOS: 98, 104, 110, 116, 122, 128, 467, and 469),
    - ii. an LCDR2 sequence selected from Table A (SEQ ID NOS: 100, 106, 112, 118, and 124);
    - iii. an LCDR3 sequence selected from Table A (SEQ ID NOS: 102, 108, 263, 120, and 126),
  - b. the TL1A binding entity heavy chain sequence comprises:
    - i. an HCDR1 sequence selected from Table A (SEQ ID NOS: 164, 170, 182, and 188),
    - ii. an HCDR2 sequence selected from Table A (SEQ ID NOS: 166, 172, 178, 184, 190, 196, 202, 483, and 485), and
    - iii. an HCDR3 sequence selected from Table A (SEQ ID NOS: 168, 174, 180, 186, 192, and 489).
- 58. The antigen binding protein of claim 55, wherein:

- a. the TL1A binding entity heavy chain variable domain comprises a heavy chain variable domain sequence selected from Table D (SEQ ID NOS: 8, 12, 16, 20, 24, 28, and 32);
  - b. the TL1A binding entity light chain variable domain comprises a light chain variable domain sequence selected from Table D (SEQ ID NOS: 6, 10, 14, 18, 22, 26, and 30);
  - c. the TNF- $\alpha$  binding entity light chain variable domain sequence is selected from Table H (SEQ ID NOS: 2, 42, 38, and 34) and
  - d. the TNF- $\alpha$  binding entity heavy chain variable domain sequence is selected from Table H (SEQ ID NOS: 4, 44, 318, 40, and 36).
59. The antigen binding protein of claim 55, wherein the TL1A binding entity heavy chain variable domain comprises a cysteine residue at position 44 and the TL1A binding entity light chain binding domain comprises a cysteine residue at position 100, numbering as in Kabat.
60. The antigen binding protein of claim 55, wherein the protein comprises the heavy and light chain sequences of an antigen binding protein selected from Table M, SEQ ID NOS:
- a. 82 and 46,
  - b. 284 and 46,
  - c. 286 and 46,
  - d. 441 and 453
  - e. 312 and 46,
  - f. 445 and 453,
  - g. 314 and 84,
  - h. 320 and 84,
  - i. 322 and 84,
  - j. 345 and 84,
  - k. 347 and 78,
  - l. 349 and 78,
  - m. 351 and 78,
  - n. 353 and 78,
  - o. 379 and 46,
  - p. 381 and 46,

- q. 383 and 84,
  - r. 385 and 84,
  - s. 387 and 78,
  - t. 389 and 78,
  - u. 433 and 451,
  - v. 427 and 449,
  - w. 429 and 449,
  - x. 431 and 451,
  - y. 433 and 451,
  - z. 435 and 451,
  - aa. 437 and 451,
  - bb. 439 and 453,
  - cc. 441 and 453,
  - dd. 443 and 453, and
  - ee. 445 and 453.
61. The antigen binding protein of claim 55 comprising SEQ ID NOS:
- a. 441 and 453;
  - b. 433 and 451; or
  - c. 445 and 453.
62. One or more isolated nucleic acids encoding the antigen binding protein of any one of claims 1 to 61 and 105 to 135.
63. One or more expression vectors comprising the nucleic acid or acids of claim 62.
64. A host cell comprising the one or more expression vectors of claim 63.
65. A method for the preparation of an antigen binding protein, comprising:
- a. culturing the host cell of claim 64 under conditions that allow expression of the antigen binding protein; and
  - b. recovering the antigen binding protein from the culture.
66. A pharmaceutical composition comprising the antigen binding protein of any one of claims 1 to 61 and a pharmaceutically acceptable diluent, excipient or carrier.

67. A method for treating a condition associated with TL1A and/or TNF- $\alpha$  in a patient in need thereof, comprising administering to the patient an effective amount of the antigen binding protein of any one of claims 1 to 61 and 105 to 135.
68. The method of claim 67, wherein the condition is inflammatory bowel disease, Crohn's disease, or ulcerative colitis.
69. Use of the antigen binding protein of any one of claims 1 to 61 and 105 to 135 in the preparation of a medicament for treating a condition associated with TL1A in a patient in need thereof.
70. The use of claim 68 wherein the condition is inflammatory bowel disease, Crohn's disease or ulcerative colitis.
71. The antigen binding protein of any one of claims 1 to 61 and 105 to 135 for use in a method for treating a condition associated with TL1A and/or TNF- $\alpha$  in a patient in need thereof.
72. The antigen binding protein of claim 71 wherein the condition is inflammatory bowel disease, Crohn's disease, or ulcerative colitis.
73. An antigen binding protein specific for TL1A wherein:
  - a. the antigen binding protein has one or two light chain variable domains and one or two heavy chain variable domains;
  - b. the light chain variable domain comprises a LCDR1, LCDR2, and LCDR3;
  - c. the heavy chain variable domain comprises a HCDR1, HCDR2, and HCDR3; and
  - d. the HCDR1 has a sequence selected from Tables A, B, and C (SEQ ID NOS: 164, 170, 182, 188, 777, 783, 792, 798, 804, 809, 815, 819, 265, 836, 847, 857, 639, 654, 655, 632, 664, 955, 979, 994, 1010, 1017, 1022, 1027, 1028, 1029, 1037, 1045, 1087, 253, 256, 259, 262, 268, 271, 265, and 950);
  - e. the HCDR2 has a sequence selected from Tables A, B, and C (SEQ ID NOS: 166, 172, 178, 184, 190, 196, 202, 483, 485, 779, 785, 794, 800, 811, 817, 821, 827, 832, 838, 843, 849, 853, 859, 864, 640, 204, 678, 679, 644, 648, 649, 633, 656, 659, 660, 665, 666, 677, 114, 227, 230, 691, 715, 669, 711, 971, 972, 973, 974, 975, 980, 981, 982, 983, 984, 995, 996, 997, 998, 0999, 1011, 1023, 1030, 1038, 1039, 1040, 1041, 1042, 1046, 1047, 1048, 1058, 1059, 1060, 1061, 1062, 1066, 1067, 1068, 1069,

- 1070, 1074, 1088, 1089, 1090, 1095, 1096, 1097, 1102, 1103, 1104, 1108, 1109, 1110, 1111, 1112, 254, 260, 184, 269, 272, 266, 951, 953, 956, and 963); and
- f. the HCDR3 sequence is selected from Tables A, B, and C (SEQ ID NOS: 168, 174, 180, 186, 192, 489, 641, 645, 650, 657, 676, 657, 667, 671, 255, 258, 261, 264, 267, 270, 273, 672, and 675).
74. The antigen binding protein of claim 73, wherein the HCDR3 comprises a sequence selected from Table A (SEQ ID NOS: 168, 174, 180, 186, 192, 489, 781, 787, 796, 802, 807, 813, 823, 829, 834, 840, 845, 851, 855, and 861).
75. The antigen binding protein of claim 73, wherein the HCDR3 has a sequence selected from antibodies and 9C8 and 3B3 (SEQ ID NO: 180 and 192).
76. The antigen binding protein of claim 74, wherein:
- the HCDR1 has a sequence selected from Table A (SEQ ID NOS: 164, 170, 182, 188, 777, 783, 792, 798, 804, 809, 815, 819, 265, 836, 847, and 857) and
  - the HCDR2 has a sequence selected from Table A (SEQ ID NOS: 166, 172, 178, 184, 190, 196, 202, 483, 485, 779, 785, 794, 800, 811, 817, 821, 827, 832, 838, 843, 849, 853, 859, and 864).
77. The antigen binding protein of claim 75 wherein:
- the HCDR1 has a sequence selected from antibodies 9C8 and 3B3 (SEQ ID NO: 170 and 188) and
  - the HCDR2 has a sequence selected from antibodies 9C8 and 3B3 (SEQ ID NO: 178 and 190).
78. The antigen binding protein of claim 73 wherein the LCDR3 has a sequence selected from Tables A, B, and C (SEQ ID NOS: 102, 108, 263, 120, 126, 687, 693, 701, 707, 717, 727, 733, 739, 745, 751, 757, 763, 767, 771, 775, 637, 638, 631, 653, 663, 637, 233, 940, 978, 989, 990, 991, 992, 993, 1005, 1006, 1007, 1008, 1009, 1034, 1035, 1036, 1055, 1056, 1057, 1065, 1086, 1093, 1094, 1099, 1100, 1101, 1107, 228, 231, 234, 237, 243, 240, 674, 936, 938, 701, 707, , 949, , 942, and 944).
79. The antigen binding protein of claim 76 wherein the LCDR3 has a sequence selected from Table A (SEQ ID NOS: 102, 108, 263, 120, 126, 687, 693, 701, 707, 717, 727, 733, 739, 745, 751, 757, 763, 767, 771, and 775).

80. The antigen binding protein of claim 77 wherein the LCDR3 has a sequence selected from antibodies 9C8 and 3B3 (SEQ ID NOS: 263 and 126).
81. The antigen binding protein of claim 78 wherein:
- the LCDR1 has a sequence selected from Tables A, B, and C (SEQ ID NOS: 98, 104, 110, 116, 122, 128, 467, 469, 683, 689, 235, 697, 146, 709, 713, 719, 723, 229, 226, 741, 747, 753, 773, 635, 642, 646, 651, 658, 661, 668, 759, 743, 765, 977, 986, 987, 1001, 1016, 1021, 1025, 1031, 1032, 1033, 1044, 1053, 1064, 1072, 1078, 1079, 1080, 1106, 226, 229, 232, 235, 241, 238, , 1113, , 146, and 947) and
  - the LCDR2 has a sequence selected from Tables A, B, and C (SEQ ID NOS: 100, 106, 112, 118, 124, 235, 699, 705, 721, 725, 731, 737, 749, 755, 761, 769, 636, 643, 647, 652, 662, 789, 988, 1001, 1002, 1004, 1026, 1054, 1073, 1081, 1082, 1083, 1084, 1085, 1092, 1098, 242, 935, 148, 948, and 943).
82. The antigen binding protein of claim 79 wherein:
- the LCDR1 has a sequence selected from Table A (SEQ ID NOS: 98, 104, 110, 116, 122, 128, 467, 469, 683, 689, 235, 697, 146, 709, 713, 719, 723, 229, 226, 741, 747, 753, and 773) and
  - the LCDR2 has a sequence selected from Table A (SEQ ID NOS: 100, 106, 112, 118, 124, 685, 699, 705, 721, 725, 731, 737, 749, 755, 761, and 769).
83. The antigen binding protein of claim 80 wherein:
- the LCDR1 has a sequence selected from antibodies 9C8 and 3B3 (SEQ ID NOS: 110 and 122) and
  - the LCDR2 has a sequence selected from antibodies 9C8 and 3B3 (SEQ ID NOS: 112 and 124).
84. The antigen binding protein of claim 73 wherein the heavy chain variable domain comprises a sequence at least about 90% identical to a heavy chain variable domain sequence selected from Table D (SEQ ID NOS: 8, 12, 16, 20, 24, 28, 32, 495, 497, 868, 872, 876, 880, 884, 888, 892, 896, 900, 904, 908, 912, 916, 920, 926, 930, and 934).
85. The antigen binding protein of claim 73 wherein the heavy chain variable domain comprises a heavy chain variable domain sequence selected from Table D (SEQ ID NOS: 8, 12, 16, 20, 24, 28, 32, 495, 497, 868, 872, 876, 880, 884, 888, 892, 896, 900, 904, 908, 912, 916, 920, 926, 930, and 934).

86. The antigen binding protein of claim 73, wherein the light chain variable domain comprises a sequence at least about 90% identical to a light chain variable domain sequence selected from Table D (SEQ ID NOS: 6, 10, 14, 18, 22, 26, 30, 491, 493, 866, 870, 874, 878, 882, 886, 890, 894, 898, 902, 906, 910, 914, 918, 922, 924, 928, and 932,).
87. The antigen binding protein of claim 73, wherein the light chain variable domain comprises a light chain variable domain sequence selected from Table D (SEQ ID NOS: 6, 10, 14, 18, 22, 26, 30, 491, 493, 866, 870, 874, 878, 882, 886, 890, 894, 898, 902, 906, 910, 914, 918, 922, 924, 928, and 932).
88. The antigen binding protein of claim 84, wherein the light chain variable domain comprises a sequence at least about 90% identical to a light chain variable domain sequence selected from Table D (SEQ ID NOS: 6, 10, 14, 18, 22, 26, 30, 491, 493, 866, 870, 874, 878, 882, 886, 890, 894, 898, 902, 906, 910, 914, 918, 922, 924, 928, and 932,).
89. The antigen binding protein of claim 85, wherein the light chain variable domain comprises a light chain variable domain sequence selected from Table D (SEQ ID NOS: 6, 10, 14, 18, 22, 26, 30, 491, 493, 866, 870, 874, 878, 882, 886, 890, 894, 898, 902, 906, 910, 914, 918, 922, 924, 928, and 932).
90. The antigen binding protein of claim 73 wherein:
- the light chain variable domain sequence comprises a light chain variable domain sequence selected from antibodies 9C8 and 3B3 (SEQ ID NOS: 14 and 22) and
  - the heavy chain variable domain comprises a heavy chain variable domain sequence selected from antibodies 9C8 and 3B3 (SEQ ID NOS: 16 and 24).
91. The antigen binding protein of claim 73 wherein the protein comprises a heavy chain having a heavy chain sequence selected from Table E (SEQ ID NOS: 52, 56, 60, 64, 68, 72, 76, 457, 461, 1118, 1122, 1126, 1130, 1134, 1138, 1142, 1146, 1150, 1154, 1158, 1162, 1166, 1170, 1174, 1178, 1182, 1186 and 1190).
92. The antigen binding protein of claim 73 wherein the protein comprises a light chain having a light chain sequence selected from Table E (SEQ ID NOS: 66, 54, 58, 62, 66, 70, 74, 455, 459, 1116, 1120, 1124, 1128, 1132, 1136, 1140, 1144, 1148, 1152, 1156, 1160, 1164, 1168, 1172, 1176, 1180, 1184 and 1188).

93. The antigen binding protein of claim 73 comprising the light and heavy chain sequences of an antibody selected from Table E, SEQ ID NOS:
- a. 50 and 52,
  - b. 54 and 56,
  - c. 58 and 60,
  - d. 62 and 64,
  - e. 66 and 68,
  - f. 70 and 72,
  - g. 74 and 76,
  - h. 455 and 457,
  - i. 459 and 461,
  - j. 1116 and 1118,
  - k. 1120 and 1122,
  - l. 1124 and 1126,
  - m. 1128 and 1130,
  - n. 1132 and 1134,
  - o. 1136 and 1138,
  - p. 1140 and 1142,
  - q. 1144 and 1146,
  - r. 1148 and 1150,
  - s. 1152 and 1154,
  - t. 1156 and 1158,
  - u. 1160 and 1162,
  - v. 1164 and 1166,
  - w. 1168 and 1170,
  - x. 1172 and 1174,
  - y. 1176 and 1178,
  - z. 1180 and 1182,
  - aa. 1184 and 1186, and
  - bb. 1188 and 1190.

94. One or more isolated nucleic acids encoding the antigen binding protein of any one of claims 73 to 93.
95. One or more expression vectors comprising the nucleic acid or acids of claim 94.
96. A host cell comprising the one or more expression vectors of claim 95.
97. A method for the preparation of an antigen binding protein, comprising:
  - a. culturing the host cell of claim 96 under conditions that allow expression of the antigen binding protein; and
  - b. recovering the antigen binding protein from the culture.
98. A pharmaceutical composition comprising the antigen binding protein of any one of claims 73 to 93 and a pharmaceutically acceptable diluent, excipient or carrier.
99. A method for treating a condition associated with TL1A in a patient in need thereof, comprising administering to the patient an effective amount of the antigen binding protein of any one of claims 73 to 93.
100. The method of claim 99, wherein the condition is inflammatory bowel disease, Crohn's disease, or ulcerative colitis.
101. Use of the antigen binding protein of any one of claims 73 to 93 in the preparation of a medicament for treating a condition associated with TL1A in a patient in need thereof.
102. The use of claim 101 wherein the condition is inflammatory bowel disease, Crohn's disease, or ulcerative colitis.
103. The antigen binding protein of any one of claims 73 to 93 for use in a method for treating a condition associated with TL1A in a patient in need thereof.
104. The antigen binding protein of claim 103 wherein the condition is inflammatory bowel disease, Crohn's disease, or ulcerative colitis.
105. The antigen binding protein of claim 23, comprising:
  - a. a first polypeptide comprising a first heavy chain of a first antibody comprising a first heavy chain variable region (VH1) and a first CH1 domain, wherein the first heavy chain is fused through its C-terminus to the N-terminus of a polypeptide comprising a second heavy chain variable region of a second antibody (VH2), wherein the VH2 is fused through its C-terminus to the N-terminus of a second CH1 domain, and wherein the first antibody comprises one of the TL1A binding entity or the TNF- $\alpha$  binding entity and the second antibody comprises the other; wherein:

- i. the VH1 or first CH1 domain comprises at least one amino acid substitution to introduce a positively charged amino acid at a residue selected from the group consisting of positions 39, 44, and 183 using EU numbering; and
    - ii. the VH2 or second CH1 domain comprises at least one amino acid substitution to introduce a negatively charged amino acid at a residue selected from the group consisting of a residue that corresponds to positions 39, 44, and 183 using EU numbering; and
  - b. a second polypeptide comprising a first light chain of the first antibody of a., wherein the first light chain comprises a first light chain variable region (VL1) and a first CL region; and wherein the VL1 or first CL domain comprises at least one amino acid substitution to introduce a negatively charged amino acid at a residue selected from the group consisting of positions 38, 100, and 176 using EU numbering; and
  - c. a third polypeptide comprising a second light chain of the second antibody of a., wherein the second light chain comprises a second light chain variable region (VL2) and a second CL region; and wherein the VL1 or first CL domain comprises at least one amino acid substitution to introduce a positively charged amino acid at a residue selected from the group consisting of positions 38, 100, and 176 using EU numbering.
106. The antigen binding protein of claim 105, wherein the first heavy chain is fused to the VH2 via a peptide linker.
107. The antigen binding protein according to claim 106, wherein the peptide linker comprises a sequence selected from the group consisting of (Gly<sub>3</sub>Ser)<sub>2</sub>, (Gly<sub>4</sub>Ser)<sub>2</sub>, (Gly<sub>3</sub>Ser)<sub>3</sub>, (Gly<sub>4</sub>Ser)<sub>3</sub>, (Gly<sub>3</sub>Ser)<sub>4</sub>, (Gly<sub>4</sub>Ser)<sub>4</sub>, (Gly<sub>3</sub>Ser)<sub>5</sub>, (Gly<sub>4</sub>Ser)<sub>5</sub>, (Gly<sub>3</sub>Ser)<sub>6</sub>, and (Gly<sub>4</sub>Ser)<sub>6</sub>.
108. The antigen binding protein according to claim 105, wherein:
- a. the VH1 or first CH1 domain comprises a mutation selected from the group consisting of Q39K, G44K, and S183K using EU numbering;
  - b. the VH2 or second CH1 domain comprises a mutation selected from the group consisting of Q39E, G44E, and S183E using EU numbering;
  - c. the VL1 or first CL domain comprises a mutation selected from the group consisting of Q38E, G100E, and S176E using EU numbering; and
  - d. the VL2 or second CL domain comprises a mutation selected from the group consisting of Q38K, G100K, and S176K using EU numbering.

109. The antigen binding protein according to claim 108, wherein:
- the first CH1 domain comprises a S183K mutation using EU numbering;
  - the second CH1 domain comprises a S183E mutation using EU numbering;
  - the first CL domain comprises a S176E mutation using EU numbering; and
  - the second CL domain comprises a S176K mutation using EU numbering.
110. The antigen binding protein according to claim 108, wherein:
- the VH1 comprises a Q39K mutation and the first CH1 domain comprises a S183K mutation using EU numbering;
  - the VH2 comprises a Q39E mutation and the second CH1 domain comprises a S183E mutation using EU numbering;
  - the VL1 comprises a Q38E mutation and the first CL domain comprises a S176E mutation using EU numbering; and
  - the VL2 comprises a Q38K mutation and the second CL domain comprises a S176K mutation using EU numbering.
111. The antigen binding protein according to claim 108, wherein:
- the first CH1 domain comprises G44K and S183K mutations using EU numbering;
  - the second CH1 domain comprises G44E and S183E mutations using EU numbering;
  - the first CL domain comprises G100E and S176E mutations using EU numbering; and
  - the second CL domain comprises G100K and S176K mutations using EU numbering.
112. The antigen binding protein of claim 23, comprising:
- a first polypeptide comprising a first heavy chain of a first antibody comprising a first heavy chain variable region (VH1) and a first CH1 domain, wherein the first heavy chain is fused through its C-terminus to the N-terminus of a polypeptide comprising a second heavy chain variable region of a second antibody (VH2), wherein the VH2 is fused through its C-terminus to the N-terminus of a second CH1 domain, and wherein the first antibody comprises one of the TL1A binding entity and the TNF- $\alpha$  binding entity and the second antibody comprises the other; wherein:
    - the VH1 or first CH1 domain comprises at least one amino acid substitution to introduce a negatively charged amino acid at a residue selected from the group consisting of positions 39, 44, and 183 using EU numbering; and

- ii. the VH2 or second CH1 domain comprises at least one amino acid substitution to introduce a positively charged amino acid at a residue selected from the group consisting of a residue that corresponds to positions 39, 44, and 183 using EU numbering; and
  - a. a second polypeptide comprising a first light chain of the first antibody of a., wherein the first light chain comprises a first light chain variable region (VL1) and a first CL region; and wherein the VL1 or first CL domain comprises at least one amino acid substitution to introduce a positively charged amino acid at a residue selected from the group consisting of positions 38, 100, and 176 using EU numbering; and
  - b. a third polypeptide comprising a second light chain of the second antibody of a., wherein the second light chain comprises a second light chain variable region (VL2) and a second CL region; and wherein the VL1 or first CL domain comprises at least one amino acid substitution to introduce a negatively charged amino acid at a residue selected from the group consisting of positions 38, 100, and 176 using EU numbering.
113. The antigen binding protein according to claim 112, wherein the first heavy chain is fused to the VH2 via a peptide linker.
114. The antigen binding protein according to claim 113, wherein the peptide linker comprises a sequence selected from the group consisting of (Gly<sub>3</sub>Ser)<sub>2</sub>, (Gly<sub>4</sub>Ser)<sub>2</sub>, (Gly<sub>3</sub>Ser)<sub>3</sub>, (Gly<sub>4</sub>Ser)<sub>3</sub>, (Gly<sub>3</sub>Ser)<sub>4</sub>, (Gly<sub>4</sub>Ser)<sub>4</sub>, (Gly<sub>3</sub>Ser)<sub>5</sub>, (Gly<sub>4</sub>Ser)<sub>5</sub>, (Gly<sub>3</sub>Ser)<sub>6</sub>, and (Gly<sub>4</sub>Ser)<sub>6</sub>.
115. The antigen binding protein according to claim 112, wherein:
- a. the VH1 or first CH1 domain comprises a mutation selected from the group consisting of Q39E, G44E, and S183E using EU numbering;
  - b. the VH2 or second CH1 domain comprises a mutation selected from the group consisting of Q39K, G44K, and S183K using EU numbering;
  - c. the VL1 or first CL domain comprises a mutation selected from the group consisting of Q38K, G100K, and S176K using EU numbering; and
  - d. the VL2 or second CL domain comprises a mutation selected from the group consisting of Q38E, G100E, and S176E using EU numbering.
116. The antigen binding protein according to claim 115, wherein:
- a. the first CH1 domain comprises a S183E mutation using EU numbering;
  - b. the second CH1 domain comprises a S183K mutation using EU numbering;

- c. the first CL domain comprises a S176K mutation using EU numbering; and
  - d. the second CL domain comprises a S176E mutation using EU numbering.
117. The antigen binding protein according to claim 115, wherein:
- a. the VH1 comprises a Q39E mutation and the first CH1 domain comprises a S183E mutation using EU numbering;
  - b. the VH2 comprises a Q39K mutation and the second CH1 domain comprises a S183K mutation using EU numbering;
  - c. the VL1 comprises a Q38K mutation and the first CL domain comprises a S176K mutation using EU numbering; and
  - d. the VL2 comprises a Q38E mutation and the second CL domain comprises a S176E mutation using EU numbering.
118. The antigen binding protein according to claim 115, wherein:
- a. the first CH1 domain comprises G44E and S183E mutations using EU numbering;
  - b. the second CH1 domain comprises G44K and S183K mutations using EU numbering;
  - c. the first CL domain comprises G100K and S176K mutations using EU numbering; and
  - d. the second CL domain comprises G100E and S176E mutations using EU numbering.
119. The antigen binding protein of claim 23, comprising:
- a. a first polypeptide comprising a first heavy chain of a first antibody comprising a first heavy chain variable region (VH1) and a first CH1 domain, wherein the first heavy chain is fused through its C-terminus to the N-terminus of a polypeptide comprising a second heavy chain variable region of a second antibody (VH2), wherein the VH2 is fused through its C-terminus to the N-terminus of a second CH1 domain, and wherein the first antibody comprises one of the TL1A binding entity and the TNF- $\alpha$  binding entity and the second antibody comprises the other; wherein:
    - i. the VH1 or first CH1 domain comprises at least one amino acid substitution to introduce a charged amino acid at a residue selected from the group consisting of positions 39, 44, and 183 using EU numbering; and
    - ii. the VH2 or second CH1 domain comprises at least one amino acid substitution to introduce a charged amino acid at a residue selected from the group consisting of a residue that corresponds to positions 39, 44, and 183 using EU numbering,

- wherein the charge is the opposite of the substituted residue of the VH1 or first CH1 of the first heavy chain; and
- b. a second polypeptide comprising a first light chain of the first antibody of a., wherein the first light chain comprises a first light chain variable region (VL1) and a first CL region; and wherein the VL1 or first CL domain comprises at least one amino acid substitution to introduce a charged amino acid at a residue selected from the group consisting of positions 38, 100, and 176 using EU numbering, wherein:
- i. the charge at position 38 is the opposite of the substituted residue of the VH1 or first CH1 of the first heavy chain at position 39 using EU numbering; the charge at position 100 using EU numbering is the opposite of the substituted residue of the VH1 or first CH1 of the first heavy chain at position 44 using EU numbering; the charge at position 176 is the opposite of the substituted residue of the VH1 or first CH1 of the first heavy chain at position 183 using EU numbering; and
- c. a third polypeptide comprising a second light chain of the second antibody of a., wherein the second light chain comprises a second light chain variable region (VL2) and a second CL region; and wherein the VL2 or second CL domain comprises at least one amino acid substitution to introduce a charged amino acid at a residue selected from the group consisting of positions 38, 100, and 176 using EU numbering, wherein:
- i. the charge at position 38 is the opposite of the substituted residue of the VH2 or second CH1 of the second heavy chain at position 39; the charge at position 100 is the opposite of the substituted residue of the VH2 or second CH1 of the second heavy chain at position 44; the charge at position 176 is the opposite of the substituted residue of the VH2 or second CH1 of the second heavy chain at position 183.
120. The antigen binding protein according to claim 119, wherein the first heavy chain is fused to the VH2 via a peptide linker.
121. The antigen binding protein according to claim 120, wherein the peptide linker comprises a sequence selected from the group consisting of (Gly<sub>3</sub>Ser)<sub>2</sub>, (Gly<sub>4</sub>Ser)<sub>2</sub>, (Gly<sub>3</sub>Ser)<sub>3</sub>, (Gly<sub>4</sub>Ser)<sub>3</sub>, (Gly<sub>3</sub>Ser)<sub>4</sub>, (Gly<sub>4</sub>Ser)<sub>4</sub>, (Gly<sub>3</sub>Ser)<sub>5</sub>, (Gly<sub>4</sub>Ser)<sub>5</sub>, (Gly<sub>3</sub>Ser)<sub>6</sub>, and (Gly<sub>4</sub>Ser)<sub>6</sub>.
122. The antigen binding protein according to claim 119, wherein:

- a. the VH1 comprises a Q39E mutation and the first CH1 domain comprises a S183K mutation using EU numbering;
  - b. the VH2 comprises a Q39K mutation and the second CH1 domain comprises a S183E mutation using EU numbering;
  - c. the VL1 comprises a Q38K mutation and the first CL domain comprises a S176E mutation using EU numbering; and
  - d. the VL2 comprises a Q38E mutation and the second CL domain comprises a S176K mutation using EU numbering.
123. The antigen binding protein according to claim 122, wherein:
- a. the first CH1 domain comprises G44E and S183K mutations using EU numbering;
  - b. the second CH1 domain comprises G44K and S183E mutations using EU numbering;
  - c. the first CL domain comprises G100K and S176E mutations using EU numbering;  
and
  - d. the second CL domain comprises G100E and S176K mutations using EU numbering.
124. The antigen binding protein according to claim 122, wherein:
- a. the VH1 comprises a Q39K mutation and the first CH1 domain comprises a S183E mutation using EU numbering;
  - b. the VH2 comprises a Q39E mutation and the second CH1 domain comprises a S183K mutation using EU numbering;
  - c. the VL1 comprises a Q38E mutation and the first CL domain comprises a S176K mutation using EU numbering; and
  - d. the VL2 comprises a Q38K mutation and the second CL domain comprises a S176E mutation using EU numbering.
125. The antigen binding protein according to claim 122, wherein:
- a. the first CH1 domain comprises G44K and S183E mutations using EU numbering;
  - b. the second CH1 domain comprises G44E and S183K mutations using EU numbering;
  - c. the first CL domain comprises G100E and S176K mutations using EU numbering;  
and
  - d. the second CL domain comprises G100K and S176E mutations using EU numbering.
126. The antigen binding protein of claim 23, comprising:

- a. a first polypeptide comprising a first heavy chain (VH2-CH1-CH2-CH3) from a first antibody, wherein the first heavy chain is fused at its carboxyl terminus (optionally through a peptide linker) to a polypeptide comprising VH2-CH1 domains of a second antibody,
- b. a second polypeptide comprising a light chain from the first antibody (VL1-CL) and
- c. a third polypeptide comprising VL2-CL domains of the second antibody;

wherein the first antibody comprises one of a TL1A binding entity and a TNF- $\alpha$  binding entity and the second antibody comprises the other.

127. The antigen binding protein of claim 126, wherein:

- a. CL from the first antibody comprises E at position 230, CH1 from the first antibody comprises K at position 230, CL from the second antibody comprises K at position 230, and CH1 from the second antibody comprises E at position 230;
- b. CL from the first antibody comprises E at position 230, CH1 from the first antibody comprises K at position 230, VL from the first antibody comprises E at position 46, VH from the first antibody comprises K at position 46, CL from the second antibody comprises K at position 230, CH1 from the second antibody comprises E at position 230, VL from the second antibody comprises E at position 46, and VH from the second antibody comprises K at position 46; or
- c. CL from the first antibody comprises E at position 230, CH1 from the first antibody comprises K at position 230, VL from the first antibody comprises E at position 141, VH from the first antibody comprises K at position 51, CL from the second antibody comprises K at position 230, CH1 from the second antibody comprises E at position 230, VL from the second antibody comprises E at position 51, and VH from the second antibody comprises K at position 141;

wherein all positions are according to EU numbering.

128. The antigen binding protein of claim 23, comprising:

- a. a first polypeptide comprising VH1-CL-CH2-CH3 domains of a first antibody fused at their carboxyl terminus (optionally through a peptide linker) to a polypeptide comprising VH2-CH1 domains of a second antibody,
- b. a second polypeptide comprising a light chain from the first antibody (VL1-CH1) and
- c. a third polypeptide comprising VL2-CL domains of the second antibody;

wherein the first antibody comprises one of a TL1A binding entity or a TNF- $\alpha$  binding entity and the second antibody comprises the other.

129. The antigen binding protein of claim 128, wherein:
- a. CL from the first antibody comprises K at position 230, CH1 from the first antibody comprises E at position 230, CL from the second antibody comprises K at position 230, and CH1 from the second antibody comprises E at position 230;
  - b. CL from the first antibody comprises K at position 230, CH1 from the first antibody comprises E at position 230, VL from the first antibody comprises E at position 46, VH from the first antibody comprises K at position 46, CL from the second antibody comprises K at position 230, CH1 from the second antibody comprises E at position 230, VL from the second antibody comprises E at position 46, and VH from the second antibody comprises K at position 46; or
  - c. CL from the first antibody comprises K at position 230, CH1 from the first antibody comprises E at position 230, VL from the first antibody comprises E at position 141, VH from the first antibody comprises K at position 51, CL from the second antibody comprises K at position 230, CH1 from the second antibody comprises E at position 230, VL from the second antibody comprises E at position 51, and VH from the second antibody comprises K at position 141;

wherein all positions are according to EU numbering.

130. The antigen binding protein of claim 23, comprising:
- a. a first polypeptide comprising a first heavy chain (VH1-CH1-CH2-CH3) of a first antibody, wherein the first heavy chain is fused at its carboxyl terminus (optionally through a peptide linker) to a polypeptide comprising VH2-CL domains of a second antibody,
  - b. a second polypeptide comprising a light chain from a first antibody (VL1-CL) and
  - c. a third polypeptide comprising VL2-CH1 domains of the second antibody;

wherein the first antibody comprises one of a TL1A binding entity or a TNF- $\alpha$  binding entity and the second antibody comprises the other.

131. The antigen binding protein of claim 130, wherein:

- a. CL from the first antibody comprises E at position 230, CH1 from the first antibody comprises K at position 230, CL from the second antibody comprises E at position 230, and CH1 from the second antibody comprises K at position 230;
- b. CL from the first antibody comprises E at position 230, CH1 from the first antibody comprises K at position 230, VL from the first antibody comprises E at position 46, VH from the first antibody comprises K at position 46, CL from the second antibody comprises E at position 230, CH1 from the second antibody comprises K at position 230, VL from the second antibody comprises E at position 46, and VH from the second antibody comprises K at position 46; or
- c. CL from the first antibody comprises E at position 230, CH1 from the first antibody comprises K at position 230, VL from the first antibody comprises E at position 141, VH from the first antibody comprises K at position 51, CL from the second antibody comprises E at position 230, CH1 from the second antibody comprises K at position 230, VL from the second antibody comprises E at position 51, and VH from the second antibody comprises K at position 141;

wherein all positions are according to EU numbering.

132. The antigen binding protein of claim 23, comprising:
  - a. a first polypeptide comprising VH1-CL-CH2-CH3 domains of a first antibody fused at their carboxyl terminus (optionally through a peptide linker) to a polypeptide comprising VH2-CL domains of a second antibody,
  - b. a second polypeptide comprising VL1-CH1 domains from the first antibody and
  - c. a third polypeptide comprising VL2-CH1 domains of the second antibody;wherein the first antibody comprises one of a TL1A binding entity or a TNF- $\alpha$  binding entity and the second antibody comprises the other.
133. The antigen binding protein of claim 132, wherein:
  - a. CL from the first antibody comprises K at position 230, CH1 from the first antibody comprises E at position 230, CL from the second antibody comprises E at position 230, and CH1 from the second antibody comprises K at position 230;
  - b. CL from the first antibody comprises K at position 230, CH1 from the first antibody comprises E at position 230, VL from the first antibody comprises E at position 46, VH from the first antibody comprises K at position 46, CL from the second antibody

comprises E at position 230, CH1 from the second antibody comprises K at position 230, VL from the second antibody comprises E at position 46, and VH from the second antibody comprises K at position 46; or

- c. CL from the first antibody comprises K at position 230, CH1 from the first antibody comprises E at position 230, VL from the first antibody comprises E at position 141, VH from the first antibody comprises K at position 51, CL from the second antibody comprises E at position 230, CH1 from the second antibody comprises K at position 230, VL from the second antibody comprises E at position 51, and VH from the second antibody comprises K at position 141;

wherein all positions are according to EU numbering.

134. The antigen binding protein according to claims 105, 112, 119, 126, 128, 130, and 132 wherein the antigen binding protein comprises:
- a. CDRL1, CDRL2, and CDRL3 amino acid sequences selected from Table 21.2A, SEQ ID NOS:
- i. 92, 110, 122, 128, and 146;
  - ii. 112, 118, 124, 148, and 242;
  - iii. 96, 108, 120, 126 and 150; and
- b. CDRH1, CDRH2, and CDRH3 amino acid sequences selected from Table 21.2B, SEQ ID NOS:
- i. 158, 170, 182, 188, and 212;
  - ii. 160, 190, 196, 214, and 633;
  - iii. 162, 180, 186, 192 and 216.
135. The antigen binding protein according to claims 105, 112, 119, 126, 128, 130, and 132 wherein the antigen binding protein comprises sequences of an antigen binding protein selected from Table 21.1, SEQ ID NOS:
- a. 1254, 1256, and 1258;
  - b. 1260, 1262, and 1264;
  - c. 1266, 1268, and 1270;
  - d. 1272, 1274, and 1276;
  - e. 1278, 1280, and 1282;
  - f. 1284, 1286, and 1288;

g.	1290, 1292, and 1294;
h.	1296, 1298, and 1300;
i.	1302, 1304, and 1306;
j.	1308, 1310, and 1312;
k.	1314, 1316, and 1318;
l.	1320, 1322, and 1324;
m.	1326, 1328, and 1330;
n.	1332, 1334, and 1336;
o.	1338, 1340, and 1342;
p.	1344, 1346, and 1348;
q.	1350, 1352, and 1354;
r.	1356, 1358, and 1360;
s.	1362, 1364, and 1366;
t.	1368, 1370, and 1372;
u.	1374, 1376, and 1378;
v.	1380, 1382, and 1384;
w.	1386, 1388, and 1390;
x.	1392, 1394, and 1396;
y.	1398, 1400, and 1402;
z.	1404, 1406, and 1408;
aa.	1410, 1412, and 1414;
bb.	1416, 1418, and 1420;
cc.	1422, 1424, and 1426;
dd.	1428, 1430, and 1432;
ee.	1434, 1436, and 1438;
ff.	1440, 1442, and 1444;
gg.	1446, 1448, and 1450;
hh.	1452, 1454, and 1456;
ii.	1458, 1460, and 1462;
jj.	1464, 1466, and 1468;
kk.	1470, 1472, and 1474;

ll.	1476, 1478, and 1480;
mm.	1482, 1484, and 1486;
nn.	1488, 1490, and 1492;
oo.	1494, 1496, and 1498;
pp.	1500, 1502, and 1504;
qq.	1506, 1508, and 1510;
rr.	1512, 1514, and 1516;
ss.	1518, 1520, and 1522;
tt.	1524, 1526, and 1528;
uu.	1530, 1532, and 1534;
vv.	1536, 1538, and 1540;
ww.	1542, 1544, and 1546;
xx.	1548, 1550, and 1552;
yy.	1554, 1556, and 1558;
zz.	1560, 1562, and 1564;
aaa.	1566, 1568, and 1570;
bbb.	1572, 1574, and 1576;
ccc.	1578, 1580, and 1582;
ddd.	1584, 1586, and 1588;
eee.	1590, 1592, and 1594;
fff.	1596, 1598, and 1600;
ggg.	1602, 1604, and 1606;
hhh.	1608, 1610, and 1612;
iii.	1614, 1616, and 1618;
jjj.	1620, 1622, and 1624;
kkk.	1626, 1628, and 1630;
lll.	1632, 1634, and 1636;
mmm.	1638, 1640, and 1642;
nnn.	1644, 1646, and 1648;
ooo.	1650, 1652, and 1654;
ppp.	1656, 1658, and 1660;

qqq.	1662, 1664, and 1666;
rrr.	1668, 1670, and 1672;
sss.	1674, 1676, and 1678;
ttt.	1680, 1682, and 1684;
uuu.	1686, 1688, and 1690;
vvv.	1692, 1694, and 1696;
www.	1698, 1700, 1702;
xxx.	1704, 1706, and 1708;
yyy.	1710, 1712, and 1714;
zzz.	1716, 1718, and 1720;
aaaa.	1722, 1724, and 1726;
bbbb.	1728, 1730, and 1732;
cccc.	1734, 1736, and 1738;
dddd.	1740, 1742, and 1744;
eeee.	1746, 1748, and 1750;
ffff.	1752, 1754, and 1756;
gggg.	1758, 1760, and 1762;
hhhh.	1764, 1766, and 1768;
iiii.	1770, 1772, and 1774;
jjjj.	1776, 1778, and 1780;
kkkk.	1782, 1784, and 1786;
llll.	1788, 1790, and 1792;
mmmm.	1794, 1796, and 1798;
nnnn.	1800, 1802, and 1804;
oooo.	1806, 1808, and 1810;
pppp.	1812, 1814, and 1816;
qqqq.	1818, 1820, and 1822;
rrrr.	1824, 1826, and 1828;
ssss.	1830, 1832, and 1834;
tttt.	1836, 1838, and 1840;
uuuu.	1842, 1844, and 1846;

vvvv.	1848, 1950, and 1852;
www.	1854, 1856, and 1858;
xxxx.	1860, 1862, and 1864;
yyyy.	1866, 1868, and 1870;
zzzz.	1872, 1874, and 1876;
aaaa.	1878, 1880, and 1882;
bbbb.	1884, 1886, and 1888;
cccc.	1890, 1892, and 1894;
dddd.	1896, 1898, and 1900;
eeee.	1902, 1904, and 1906;
ffff.	1908, 1910, and 1912;
gggg.	1914, 1916, and 1918;
hhhh.	1920, 1922, and 1924;
iiii.	1926, 1928, and 1930;
jjjj.	1932, 1934, and 1936;
kkkk.	1938, 1940, and 1942;
llll.	1944, 1946, and 1948;
mmmm.	1950, 1952, and 1954;
nnnn.	1956, 1958, and 1960;
oooo.	1962, 1964, and 1966;
pppp.	1968, 1970, and 1972;
qqqq.	1974, 1976, and 1978;
rrrr.	1980, 1982, and 1984;
ssss.	1986, 1988, and 1990;
tttt.	1992, 1994, and 1996;
uuuu.	1998, 2000, and 2002;
vvvv.	2004, 2006, and 2008;
www.	2010, 2012, and 2014;
xxxx.	2016, 2018, and 2020;
yyyy.	2022, 2024, and 2026;
zzzz.	2028, 2030, and 2032;

aaaaaa.	2034, 2036, and 2038;
bbbbbb.	2040, 2042, and 2044;
cccccc.	2046, 2048, and 2050;
dddddd.	2052, 2054, and 2056;
eeeeee.	2058, 2060, and 2062;
ffffff.	2064, 2066, and 2068;
gggggg.	2070, 2072, and 2074;
hhhhhh.	2076, 2078, and 2080;
iiiiii.	2082, 2084, and 2086;
jjjjjj.	2088, 2090, and 2092;
kkkkkk.	2094, 2096, and 2098;
llllll.	2100, 2102, and 2104;
mmmmmm.	2106, 2108, and 2110; and
nnnnnn.	2112, 2114, and 2116.